Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
抗生素和抗病毒
/
抗感染
功能 结构
/
Antibacterial
大环内酯类 抗细菌抗生素
/ Erythromycin/红霉素

Erythromycin/红霉素 {[allProObj[0].p_purity_real_show]}

货号：A199997 同义名： NSC 55929; E-Mycin

Erythromycin是红霉素链霉菌产生的抗生素，主要成分为红霉素A和少量红霉素B和C，推荐使用浓度为100 mg/L（有效范围50-200 mg/L），Erythromycin既能抑制细菌生长，又可作为胃动素受体激动剂阻断人气道呼吸糖结合物分泌，并用于重组乳酸链球菌质粒固化筛选。

Erythromycin/红霉素 化学结构 CAS号：114-07-8
Erythromycin/红霉素 化学结构
CAS号：114-07-8
Erythromycin/红霉素 3D分子结构
CAS号：114-07-8
Erythromycin/红霉素 化学结构 CAS号：114-07-8
Erythromycin/红霉素 3D分子结构 CAS号：114-07-8
规格 价格 会员价 库存 数量
{[ item.pr_size ]} {[ size_append(item.pr_size_append, item.pr_am, item.pr_size) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} 		{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Erythromycin/红霉素 纯度/质量文件 产品仅供科研

货号：A199997 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
• Cell, 2025, 188, (21): 5847-5861.e11. Ambeed. [ A122167 ]
• Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
• Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
• Nat. Nanotechnol., 2025, 20, 1502-1513. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >

Erythromycin/红霉素 生物活性

描述 Erythromycin is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity[3]. Erythromycin inhibited growth of P. falciparum with IC50 and IC90 values of 58.2 ± 7.7 microM and 104.0 ± 10.8 microM, respectively. Combinations of chloroquine with erythromycin showed synergistic effects against parasite growth in vitro[4]. The most common side effect of erythromycin is gastrointestinal intolerance, which appears to be related to disruption of intestinal motility[5]. First generation derivatives such as 2'-esters and acid-addition salts significantly improved the chemical stability and oral bioavailability of erythromycin[6].
体外研究 Erythromycin inhibited the growth of P. falciparum with IC50 and IC90 values of 58.2 μM and 104.0 μM, respectively[7]. Erythromycin (10 μM, 100 μM; 24 h, 72 h) had antioxidant and anti-inflammatory effects, inhibited the accumulation of 4-HNE (p<0.01) and 8-OHdG (p<0.01), and significantly reduced the expression of Iba-1 (p<0.01) and TNF-α (p<0.01).[8].

Erythromycin/红霉素 细胞实验

Cell Line
Concentration Treated Time Description References
Murine articular chondrocytes 10, 25 µM 1 hour To investigate the association of EM with the ghrelin receptor. The binding of EM to chondrocytes is mediated by the ghrelin receptor. Biochem Pharmacol. 2019 Jul;165:79-90.
Nonfermenting gram-negative bacilli 0.049-50.0 μg/ml 18-24 hours Compare the in vitro inhibitory activity of erythromycin and rosamicin against nonfermenting gram-negative bacilli. Results showed that rosamicin was at least fourfold more active than erythromycin against most strains tested. Antimicrob Agents Chemother. 1978 Aug;14(2):274-6.
Human lung adenocarcinoma cell line A549 10 mg/ml 30 minutes To investigate the effect of erythromycin and clarithromycin on growth factor-induced heparanase mRNA expression. Results showed that EM suppressed heparanase mRNA expression induced by PDGF and HGF, but not by bFGF, while CAM suppressed expression induced by bFGF but not by PDGF or HGF. Mediators Inflamm. 2001 Oct;10(5):259-67.
Primary human articular chondrocytes (nHACs) 1, 10, 100 µM 4 days To evaluate EM activity on human articular chondrocytes under inflammatory conditions. EM inhibited IL-1β-induced catabolic gene expression and NF-κB activation. Biochem Pharmacol. 2019 Jul;165:79-90.
Actinobacillus actinomycetemcomitans 0.5 to 8.0 μg/mL 48 hours To compare the in vitro activities of erythromycin and azithromycin against Actinobacillus actinomycetemcomitans, results showed that erythromycin had poor in vitro activity against A. actinomycetemcomitans. Antimicrob Agents Chemother. 1992 Jun;36(6):1241-3.
Mycobacterium avium complex 64 μg/mL 5-21 days To test the in vitro activity of erythromycin against the M. avium complex, the results showed that the MIC of erythromycin was 64 μg/ml, which was 8- to 32-fold less active than clarithromycin (4 μg/ml). Antimicrob Agents Chemother. 1989 Sep;33(9):1531-4.
D98/AH-2 cells 300 μg/mL Used in cell fusion experiments to generate erythromycin-resistant cybrids. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4549-53.

Erythromycin/红霉素 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Beige mice (C57BL/6J bgJ/bgJ) M. avium ATCC 25291 infection model Subcutaneous injection 10 mg/kg and 25 mg/kg Twice daily at 8-hour intervals for 9 days To test the in vivo activity of erythromycin against M. avium, the results showed that erythromycin at doses of 10 mg/kg and 25 mg/kg did not significantly reduce the viable bacterial counts in the spleen. Antimicrob Agents Chemother. 1989 Sep;33(9):1531-4.
C57BL/6J mice Chronic smoking-induced emphysema model Oral 100 mg/kg Once daily for 12 weeks To evaluate the effect of erythromycin on NETs formation and pulmonary inflammation in a chronic smoking-induced emphysema model. Results showed that erythromycin significantly reduced NETs formation and ameliorated emphysema. Cell Death Dis. 2019 Sep 12;10(9):678
Mice MIA-induced joint inflammation and cartilage destruction model Intraperitoneal injection 40μg/g/day Daily for 7 days To evaluate the protective effect of EM on joint inflammation and cartilage destruction in vivo. EM alleviates inflammation and joint destruction through the ghrelin receptor. Biochem Pharmacol. 2019 Jul;165:79-90.
Mice Gnotobiotic mice with a defined 12-member microbiome Oral 25 mg/kg Single dose Evaluated the impact of tetracycline on gut microbiota, showing significant reduction in B. vulgatus counts post-treatment. Nature. 2021 Nov;599(7883):120-124

Erythromycin/红霉素 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02757534 Gastroparesis Phase 2 Enrolling by invitation December 2020 United States, Iowa ... 展开 >> University of Iowa Iowa City, Iowa, United States, 52242 收起 <<
NCT01173133 - Unknown December 2010 United States, California ... 展开 >> Mills Penisula Hospital Recruiting Burlingame, California, United States, 94010-3282 Contact: John Griffin, MD    650-348-1503       Principal Investigator: John Griffin, MD 收起 <<
NCT01424254 Gastrointestinal Bleeding Phase 3 Completed - Canada, Quebec ... 展开 >> Montreal General Hospital Montreal, Quebec, Canada, H3G1A4 收起 <<

Erythromycin/红霉素 参考文献

[1]Peeters T, Matthijs G, et al. Erythromycin is a motilin receptor agonist. Am J Physiol. 1989 Sep;257(3 Pt 1):G470-4.

[2]McCormack WM, George H, et al. Hepatotoxicity of erythromycin estolate during pregnancy. Antimicrob Agents Chemother. 1977 Nov;12(5):630-5.

[3]Brittain DC. Erythromycin. Med Clin North Am. 1987;71(6):1147–1154

[4]Nakornchai S, Konthiang P. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop. 2006;100(3):185–191

[5]Nakornchai S, Konthiang P. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop. 2006;100(3):185–191

[6]Nakornchai S, Konthiang P. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop. 2006;100(3):185–191

[7]Gribble MJ, et al. Erythromycin. Med Clin North Am. 1982 Jan;66(1):79-89.

[8]Katayama Y, et al. Neuroprotective effects of erythromycin on cerebral ischemia reperfusion-injury and cell viability after oxygen-glucose deprivation in cultured neuronal cells. Brain Res. 2014 Nov 7. 1588:159-67.

Erythromycin/红霉素 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.36mL

0.27mL

0.14mL

6.81mL

1.36mL

0.68mL

13.63mL

2.73mL

1.36mL

Erythromycin/红霉素 技术信息

CAS号114-07-8
分子式C37H67NO13
分子量 733.93
SMILES Code C[C@@H]([C@@H]([C@H](C(O[C@@H]([C@@](O)([C@@H]([C@H](C([C@@H](C[C@]1(O)C)C)=O)C)O)C)CC)=O)C)O[C@H]2C[C@](C)([C@H]([C@@H](O2)C)O)OC)[C@H]1O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O
MDL No. MFCD00084654
别名 NSC 55929; E-Mycin; Eryc-250; Eryc-125; HSDB 3074
运输蓝冰
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry,2-8°C
溶解方案

DMSO: 105 mg/mL(143.07 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案 一
方案 二
方案 三
配制的工作液建议现用现配，短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。
方案 一

Tags: Erythromycin/红霉素 |Erythromycin/红霉素 | NSC 55929 | E-Mycin | Eryc-250 | Eryc-125 | HSDB 3074 | 114-07-8 | Antibacterial | 大环内酯类 | 抗细菌抗生素 | Erythromycin/红霉素 纯度/质量文件 | Erythromycin/红霉素 生物活性 | Erythromycin/红霉素 临床数据 | Erythromycin/红霉素 参考文献 | Erythromycin/红霉素 实验方案 | Erythromycin/红霉素 技术信息

AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 AmBeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z